WORKSHOP A
Exploring Engineering and Manufacturing Techniques for Multi-Targeted Cell Therapies
9:00 - 11:00
Workshop Leaders
Reviewing existing gene engineering approaches being leveraged in the clinic, and their relative advantages and disadvantages
Investigating the effects of engineering techniques on cell fitness, target molecule expression, and random insertion
Discussing strategies to drive the feasibility of complex ‘decisionmaking’ CARs with logic gates and multi-functional cells, and the different cell modalities to consider
Sharing thoughts on how to advance next-generation cell immunotherapies
Considering what a manufacturing process might look like to express multiple genes or entities, and whether approaches could be sequential or simultaneous
Juan Vera
CTO
Marker Therapeutics
Shon Green
Senior Director
Translational R&D
Umoja Therapeutics
Sicco Popma
President & CEO
IO Bio Science
WORKSHOP B
Identifying Clinically Relevant Targets & Best Approaches to Investigating Safety
14:00 - 16:00
Workshop Leaders
Optimizing target selection & characterization of dual-target therapies
Addressing translational challenges to maintain therapeutic safety and efficacy with multi-targeted approaches
Implementing platforms for safety assessment, and discussing how appropriate existing and emerging safety studies are for cell immunotherapies
Examining targets to identify combination mechanisms, with high safety and efficacy
Eduardo Laborda
Associate Director Immuno-Oncology
Calibr at Scripps Research
Hanspeter Gerber
CSO
3T Biosciences
